106 related articles for article (PubMed ID: 7974375)
1. Increased mononuclear cell tissue factor and type-2 plasminogen activator inhibitor and reduced plasma fibrinolytic capacity in children with lymphoma.
Semeraro N; Montemurro P; Giordano P; Santoro N; De Mattia D; Colucci M
Thromb Haemost; 1994 Jul; 72(1):54-7. PubMed ID: 7974375
[TBL] [Abstract][Full Text] [Related]
2. Changes in coagulation-fibrinolysis balance in blood mononuclear cells and in gastric mucosa from patients with Helicobacter pylori infection.
Colucci M; Rossiello MR; Pentimone A; Berloco P; Russo F; Di Leo A; Semeraro N
Thromb Res; 2005; 116(6):471-7. PubMed ID: 16181982
[TBL] [Abstract][Full Text] [Related]
3. Cultured human mesangial cells produce both type 1 and type 2 plasminogen activator inhibitors.
Colucci M; Gesualdo L; Montemurro P; Cavallo LG; Conese M; Mascolo E; Ranieri E; Di Paolo S; Schena FP; Semeraro N
Thromb Haemost; 1995 Dec; 74(6):1516-20. PubMed ID: 8772230
[TBL] [Abstract][Full Text] [Related]
4. [Changes of blood coagulative and fibrinolytic system and function of pulmonary vascular endothelium after therapy in patients with acute pulmonary thromboembolism].
Pang BS; Wang C; Lu Y; Yang YH; Xing GH; Mao YL; Huang XX; Zhai ZG
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3074-8. PubMed ID: 18261355
[TBL] [Abstract][Full Text] [Related]
5. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
7. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
[TBL] [Abstract][Full Text] [Related]
8. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
9. [Activation of fibrynolysis in children with chronic B or C hepatitis].
Michalska K; Szaflarska-Popławska A; Dymek G; Kotschy M
Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691
[TBL] [Abstract][Full Text] [Related]
10. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis.
Kotani I; Sato A; Hayakawa H; Urano T; Takada Y; Takada A
Thromb Res; 1995 Mar; 77(6):493-504. PubMed ID: 7624837
[TBL] [Abstract][Full Text] [Related]
11. Biological effects of combined inactivation of plasminogen activator and plasminogen activator inhibitor-1 gene function in mice.
Lijnen HR; Moons L; Beelen V; Carmelie P; Collen D
Thromb Haemost; 1995 Oct; 74(4):1126-31. PubMed ID: 8560424
[TBL] [Abstract][Full Text] [Related]
12. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
13. Impaired fibrinolysis in obstructive jaundice--evidence from clinical and experimental studies.
Colucci M; Altomare DF; Chetta G; Triggiani R; Cavallo LG; Semeraro N
Thromb Haemost; 1988 Aug; 60(1):25-9. PubMed ID: 3142090
[TBL] [Abstract][Full Text] [Related]
14. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
15. Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease.
Günther A; Mosavi P; Ruppert C; Heinemann S; Temmesfeld B; Velcovsky HG; Morr H; Grimminger F; Walmrath D; Seeger W
Thromb Haemost; 2000 Jun; 83(6):853-60. PubMed ID: 10896238
[TBL] [Abstract][Full Text] [Related]
16. Endothelial cell activation in cutaneous vasculitis.
Jurd KM; Stephens CJ; Black MM; Hunt BJ
Clin Exp Dermatol; 1996 Jan; 21(1):28-32. PubMed ID: 8689765
[TBL] [Abstract][Full Text] [Related]
17. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia.
Tallman MS; Lefèbvre P; Baine RM; Shoji M; Cohen I; Green D; Kwaan HC; Paietta E; Rickles FR
J Thromb Haemost; 2004 Aug; 2(8):1341-50. PubMed ID: 15304040
[TBL] [Abstract][Full Text] [Related]
18. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology.
Gris JC; Neveu S; Mares P; Biron C; Hedon B; Schved JF
J Lab Clin Med; 1993 Nov; 122(5):606-15. PubMed ID: 8228580
[TBL] [Abstract][Full Text] [Related]
19. The tissue factor and plasminogen activator inhibitor type-1 response in pediatric sepsis-induced multiple organ failure.
Green J; Doughty L; Kaplan SS; Sasser H; Carcillo JA
Thromb Haemost; 2002 Feb; 87(2):218-23. PubMed ID: 11858480
[TBL] [Abstract][Full Text] [Related]
20. Tissue-type plasminogen activator after venous occlusion in pregnancy and puerperium.
Stegnar M; Zore A; Novak-Antolic Z; Vovk N; Kruithof EK
Thromb Haemost; 1993 Sep; 70(3):486-90. PubMed ID: 8259554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]